Scalable Production of iPSC-Derived Human Neurons to Identify Tau-Lowering Compounds by High-Content Screening

[1]  Maxime W. C. Rousseaux,et al.  Reduction of Nuak1 Decreases Tau and Reverses Phenotypes in a Tauopathy Mouse Model , 2016, Neuron.

[2]  G. Logroscino,et al.  Tau-based therapeutics for Alzheimer's disease: active and passive immunotherapy. , 2016, Immunotherapy.

[3]  A. Buist,et al.  Development of a Scalable, High-Throughput-Compatible Assay to Detect Tau Aggregates Using iPSC-Derived Cortical Neurons Maintained in a Three-Dimensional Culture Format , 2016, Journal of biomolecular screening.

[4]  M. Mather,et al.  The Locus Coeruleus: Essential for Maintaining Cognitive Function and the Aging Brain , 2016, Trends in Cognitive Sciences.

[5]  S. Maeda,et al.  Toxic tau oligomer formation blocked by capping of cysteine residues with 1,2-dihydroxybenzene groups , 2015, Nature Communications.

[6]  E. Mandelkow,et al.  Tau in physiology and pathology , 2015, Nature Reviews Neuroscience.

[7]  Navjot Kaur,et al.  A Facile Method for Simultaneously Measuring Neuronal Cell Viability and Neurite Outgrowth , 2015, Current chemical genomics and translational medicine.

[8]  F. Grüninger.  Invited review: Drug development for tauopathies , 2015, Neuropathology and applied neurobiology.

[9]  Chengyu Liu,et al.  Transcription Activator-Like Effector Nuclease (TALEN)-Mediated CLYBL Targeting Enables Enhanced Transgene Expression and One-Step Generation of Dual Reporter Human Induced Pluripotent Stem Cell (iPSC) and Neural Stem Cell (NSC) Lines , 2015, PloS one.

[10]  H. Braak,et al.  Neuroanatomy and Pathology of Sporadic Alzheimer's Disease , 2014 .

[11]  A. Caccamo,et al.  Administration of a selective β2 adrenergic receptor antagonist exacerbates neuropathology and cognitive deficits in a mouse model of Alzheimer's disease , 2014, Neurobiology of Aging.

[12]  Jon W. Johnson,et al.  Large-scale generation of human iPSC-derived neural stem cells/early neural progenitor cells and their neuronal differentiation , 2014, Organogenesis.

[13]  T. Young-Pearse,et al.  Comparison and Optimization of hiPSC Forebrain Cortical Differentiation Protocols , 2014, PloS one.

[14]  S. Oddo,et al.  Genetic suppression of β2-adrenergic receptors ameliorates tau pathology in a mouse model of tauopathies. , 2014, Human molecular genetics.

[15]  Seung Woo Jung,et al.  Generation of Induced Neuronal Cells by the Single Reprogramming Factor ASCL1 , 2014, Stem cell reports.

[16]  N. Krogan,et al.  Critical Role of Acetylation in Tau-Mediated Neurodegeneration and Cognitive Deficits , 2015, Nature Medicine.

[17]  B. Conklin,et al.  Isolation of single-base genome-edited human iPS cells without antibiotic selection , 2014, Nature Methods.

[18]  P. Arlotta,et al.  Development-Inspired Reprogramming of the Mammalian Central Nervous System , 2014, Science.

[19]  Robert J. Neely,et al.  Characterization of Novel CSF Tau and ptau Biomarkers for Alzheimer’s Disease , 2013, PloS one.

[20]  J. Rogers,et al.  Allosteric Heat Shock Protein 70 Inhibitors Rapidly Rescue Synaptic Plasticity Deficits by Reducing Aberrant Tau , 2013, Biological Psychiatry.

[21]  S. Prusiner,et al.  A high-throughput screening assay for determining cellular levels of total tau protein. , 2013, Current Alzheimer research.

[22]  D. Holtzman,et al.  Antisense Reduction of Tau in Adult Mice Protects against Seizures , 2013, The Journal of Neuroscience.

[23]  T. Dawson,et al.  Identification through high‐throughput screening of 4'‐methoxyflavone and 3',4'‐dimethoxyflavone as novel neuroprotective inhibitors of parthanatos , 2013, British journal of pharmacology.

[24]  T. Südhof,et al.  Rapid Single-Step Induction of Functional Neurons from Human Pluripotent Stem Cells , 2013, Neuron.

[25]  Meaghan Morris,et al.  Age-appropriate cognition and subtle dopamine-independent motor deficits in aged Tau knockout mice , 2013, Neurobiology of Aging.

[26]  J. Rubenstein,et al.  Functional maturation of hPSC-derived forebrain interneurons requires an extended timeline and mimics human neural development. , 2013, Cell stem cell.

[27]  Shaomin Li,et al.  Environmental Novelty Activates β2-Adrenergic Signaling to Prevent the Impairment of Hippocampal LTP by Aβ Oligomers , 2013, Neuron.

[28]  H. Akiyama,et al.  Methylene Blue Reduced Abnormal Tau Accumulation in P301L Tau Transgenic Mice , 2012, PloS one.

[29]  K. Jellinger,et al.  Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature , 2012, Journal of neuropathology and experimental neurology.

[30]  Jason E Gestwicki,et al.  Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo , 2012, Autophagy.

[31]  P. Heutink,et al.  High Content Screening in Neurodegenerative Diseases , 2012, Journal of visualized experiments : JoVE.

[32]  Dietmar R. Thal,et al.  Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years , 2011, Journal of neuropathology and experimental neurology.

[33]  F. Gage,et al.  Rapid and efficient generation of functional motor neurons from human pluripotent stem cells using gene delivered transcription factor codes. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[34]  B. Hyman,et al.  Are Tangles as Toxic as They Look? , 2011, Journal of Molecular Neuroscience.

[35]  Thomas Vierbuchen,et al.  Induction of human neuronal cells by defined transcription factors , 2011, Nature.

[36]  Rudi D'Hooge,et al.  Tau-Induced Defects in Synaptic Plasticity, Learning, and Memory Are Reversible in Transgenic Mice after Switching Off the Toxic Tau Mutant , 2011, The Journal of Neuroscience.

[37]  L. Mucke,et al.  Amyloid-β/Fyn–Induced Synaptic, Network, and Cognitive Impairments Depend on Tau Levels in Multiple Mouse Models of Alzheimer's Disease , 2011, The Journal of Neuroscience.

[38]  Yadong Huang,et al.  Apolipoprotein E4 Causes Age- and Tau-Dependent Impairment of GABAergic Interneurons, Leading to Learning and Memory Deficits in Mice , 2010, The Journal of Neuroscience.

[39]  Kai Zhang,et al.  Tau Reduction Prevents Aβ-Induced Defects in Axonal Transport , 2010, Science.

[40]  Jürgen Götz,et al.  Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models , 2010, Cell.

[41]  M. Hüll,et al.  Norepinephrine enhances the LPS-induced expression of COX-2 and secretion of PGE2 in primary rat microglia , 2010, Journal of Neuroinflammation.

[42]  J. Trojanowski,et al.  Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies , 2009, Nature Reviews Drug Discovery.

[43]  L. Tan,et al.  Polymorphisms at the β2-adrenergic receptor gene influence Alzheimer's disease susceptibility , 2008, Brain Research.

[44]  L. Mucke,et al.  Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model , 2007, Science.

[45]  A. Myers,et al.  The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts , 2007, Neurobiology of Disease.

[46]  Yun Bai,et al.  Activation of β2-adrenergic receptor stimulates γ-secretase activity and accelerates amyloid plaque formation , 2006, Nature Medicine.

[47]  L. Petrucelli,et al.  Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression , 2006, Molecular Neurodegeneration.

[48]  Marc Ferrer,et al.  Robust statistical methods for hit selection in RNA interference high-throughput screening experiments. , 2006, Pharmacogenomics.

[49]  A M Pittman,et al.  The H1c haplotype at the MAPT locus is associated with Alzheimer's disease. , 2005, Human molecular genetics.

[50]  P. Hof,et al.  Cell-Cycle Reentry and Cell Death in Transgenic Mice Expressing Nonmutant Human Tau Isoforms , 2005, The Journal of Neuroscience.

[51]  P. Zbinden,et al.  High Throughput Screening of β-Amyloid Secretion Inhibitors Using Homogenous Time-Resolved Fluorescence , 2004 .

[52]  Bert Gunter,et al.  Improved Statistical Methods for Hit Selection in High-Throughput Screening , 2003, Journal of biomolecular screening.

[53]  Joshua M. Shulman,et al.  Tauopathy in Drosophila: Neurodegeneration Without Neurofibrillary Tangles , 2001, Science.

[54]  M. Tabaton,et al.  Corticobasal degeneration shares a common genetic background with progressive supranuclear palsy , 2000, Annals of neurology.

[55]  H. Geerts,et al.  Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. , 1999, The American journal of pathology.

[56]  Thomas D. Y. Chung,et al.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.

[57]  I Litvan,et al.  Association of an extended haplotype in the tau gene with progressive supranuclear palsy. , 1999, Human molecular genetics.

[58]  M. Memo,et al.  Characterization of tau proteins in human neuroblastoma SH-SY5Y cell line , 1997, Neuroscience Letters.

[59]  E. Vizi,et al.  Isoproterenol regulates tumour necrosis factor, interleukin‐10, interleukin‐6 and nitric oxide production and protects against the development of vascular hyporeactivity in endotoxaemia , 1997, Immunology.

[60]  V. Bennett,et al.  AnkyrinG. A new ankyrin gene with neural-specific isoforms localized at the axonal initial segment and node of Ranvier. , 1995, The Journal of biological chemistry.

[61]  Á. Pazos,et al.  Loss of high-affinity α 2-adrenoceptors in Alzheimer's disease: An autoradiographic study in frontal cortex and hippocampus , 1992, Neuroscience Letters.

[62]  E. Frohman,et al.  Norepinephrine inhibits gamma-interferon-induced MHC class II (Ia) antigen expression on cultured brain astrocytes , 1988, Journal of Neuroimmunology.

[63]  L. Mucke,et al.  Amyloid-beta / Fyn – Induced Synaptic , Network , and Cognitive Impairments Depend on Tau Levels in Multiple Mouse Models of Alzheimer ’ s Disease , 2015 .

[64]  H. Braak,et al.  Neuroanatomy and Pathology of Sporadic Alzheimer's Disease Prologue , 2015 .

[65]  Michael B. Stadler,et al.  Rapid neurogenesis through transcriptional activation in human stem cells , 2014 .

[66]  Joshua A Harrill,et al.  Use of high content image analyses to detect chemical-mediated effects on neurite sub-populations in primary rat cortical neurons. , 2013, Neurotoxicology.

[67]  M. Ahlijanian,et al.  Tau transgenic mice as models for cerebrospinal fluid tau biomarkers. , 2011, Journal of Alzheimer's disease : JAD.

[68]  John Q Trojanowski,et al.  Evidence that non-fibrillar tau causes pathology linked to neurodegeneration and behavioral impairments. , 2008, Journal of Alzheimer's disease : JAD.

[69]  Yun Bai,et al.  Activation of beta2-adrenergic receptor stimulates gamma-secretase activity and accelerates amyloid plaque formation. , 2006, Nature medicine.

[70]  Alexandra Flemming,et al.  Infectious disease: Unravelling SARS lethality , 2005, Nature Reviews Drug Discovery.

[71]  P. Zbinden,et al.  High throughput screening of beta-amyloid secretion inhibitors using homogenous time-resolved fluorescence. , 2004, Combinatorial chemistry & high throughput screening.